HLB Genex, Inc. Logo

HLB Genex, Inc.

Develops and produces customized enzyme and microbiome-based solutions.

187420 | KO

Overview

Corporate Details

ISIN(s):
KR7187420005
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노1로 65(관평동), 대전광역시

Description

HLB Genex, Inc. is a biotechnology company that develops and produces customized enzyme and microbiome-based solutions. The company's core activities involve the research, development, and manufacturing of industrial special enzymes and bio-healthcare ingredients. Its key products include enzymes like Lactase for food applications, Catalase for eco-friendly industrial processes, and Proteinase K for molecular diagnostics. In the bio-healthcare segment, it produces Vitamin K2 (Menaquinone 7) for bone and cardiovascular health and Phytosphingosine for cosmeceuticals. The company utilizes proprietary platform technologies, such as Microbial Surface Display and Spore Biologics, to develop its products and advance its pipeline of microbiome therapeutics by identifying effector molecules, also known as postbiotics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2019-05-15 00:00
분기보고서 (2019.03)
Korean 1.3 MB
2019-04-01 00:00
사업보고서 (2018.12)
Korean 454.8 KB
2019-03-27 00:00
정기주주총회결과
Korean 23.0 KB
2019-03-19 00:00
감사보고서제출
Korean 27.4 KB
2019-03-12 00:00
주주총회소집공고
Korean 285.1 KB
2019-03-11 00:00
주주총회소집결의
Korean 10.1 KB
2019-02-22 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 12.3 KB
2019-02-21 00:00
기업설명회(IR)개최
Korean 7.9 KB
2018-12-13 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2018-11-14 00:00
분기보고서 (2018.09)
Korean 1.2 MB
2018-11-01 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.0 KB
2018-10-22 00:00
기업설명회(IR)개최
Korean 7.2 KB
2018-10-12 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.2 KB
2018-10-12 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.2 KB
2018-10-12 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.1 KB

Automate Your Workflow. Get a real-time feed of all HLB Genex, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HLB Genex, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HLB Genex, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.